Combination of Ultrasound-Guided Percutaneous Microwave Ablation and Radioiodine Therapy in Benign Thyroid Disease: A 3-Month Follow-Up Study

Kombination von ultraschallgesteueter perkutaner Mikrowellenablation mit Radiojodtherapie zur Behandlung benigner Schilddrüsenkrankheiten – Eine 3-monatige Kontrollstudie

Authors
H. Korkusuz, C. Happel, D. A. Koch, F. Gruenwald

Affiliation
Department of Nuclear Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany

Key words
- combined therapy
- radioiodine
- microwave ablation
- thyroid function
- nodular goiter

Zusammenfassung

Ziel: Erste Studien zu verschiedenen Kombinationstherapien zur Behandlung benigner nodulärer Schilddrüsenvolumen erbrachten die Kombinations therapie. Ziel der Studie war die Effektivität der kombinierten Mikrowellenablation (MWA) und Radiojodtherapie (RIT) zu prüfen, wobei die Schilddrüsenwerte nach 3 Monaten im Fokus stand.

Material und Methoden: Fünfzehn Patienten (medianes Alter 55 Jahre) mit großen Strumen und Morbus Basedow oder benignen Schilddrüsenvolumen stellten die Kombinations therapie. Serum wurden Triiodthyronin (T3), Thyroxin (T4), Thyreoglobulin (Tg) und Antikörper gegen Thyreoglobulin (TgAK), Thyreotropin-Rezeptoren (TRAK) und Thyreoperoxidase (TPOAK) bei der 3MKU untersucht. Um die Effektivität zu ermitteln, wurden zusätzlich Schilddrüsenvolumen, benötigte I-131-Therapieaktivität und Krankenhausliegedauer analysiert. Für die unter Lokalanästhesie durchgeführte MWA wurde ein System im Wellenlängenbereich von 920 bis 928 MHz eingesetzt.

Ergebnisse: TSH, T4, T3 und Tg veränderten sich bei der 3MKU gegenüber den Initialwerten nicht; die Patienten blieben euthyreot, außer zwei Patienten, wo eine Verbesserung der initialen TSH-Werte in den Normbereich beobachtet werden konnte. Ein Patient entwickelte einen hohen TRAb-Wert, der sich jedoch wieder normalisierte. Die 3MKU ergab eine mittlere Volumenreduktion der SD um 26,4 ml ± 7,9 ml (30,5 % ± 4,6 % (p < 0,05)). Die benötigte Therapieaktivität konnte um 26,6 % ± 4,8 % (p < 0,05) und die Krankenhaus liegedauer um 30,9 % ± 19,9 % (p < 0,05) gesenkt werden.

Schlussfolgerung: Die erhobenen Daten bestätigen die Effektivität der Kombination von MWA mit RIT. Die Kombinationstherapie ist ein innovativer Ansatz zur Behandlung benigner nodularer Schilddrüsenkrankheiten.
tive and effective treatment and could in the future be a more effective alternative to surgical therapy in the treatment of benign nodular goiter. Common problems are cosmetic issues, local pain, subjective symptoms, caused by compression of the trachea or esophagus, and systemic symptoms of hyperthyroidism or anxiety about malignant change [1]. Conventional treatments of nodular goiters include thyroidec- tomy and radioiodine therapy. The surgical approach is frequently preferred for patients with nodules larger than 5 cm [2, 3]. The reason is that in large nodules with more volume, I-31 therapy is less effective and side effects are more frequent due to the higher doses required for larger volumes [4, 5]. Although surgery remains the standard of care, nonsurgical treatment may be an acceptable option. New image-guided minimally invasive approaches such as radiofrequency therapy (RFT), laser ablation therapy (LAT), percutaneous ethanol injection therapy (PEIT) and high intensity focused ultrasound (HIFU) offer an effective and less expensive alternative to surgery for treating symptomatic or enlarging nodules [6–8]. Thermal ablation with microwaves (MWA) represents a fairly new therapy for thyroid nodules. It has already been used successfully for the treatment of malignancy in the liver, lung and kidneys [9]. The technique’s effectiveness for volume reduction in thyroid nodules has been proven in various studies [1, 10, 11]. Nevertheless, these nonsurgical minimally invasive treatments have their limits, especially for the treatment of very large nodular goiters. As thermal ablation therapy would need a couple of treatment sessions and would be a lot more time-consuming, it is fairly difficult to use thermal ablation as monotherapy for the treatment of very large nodular goiters. For example, HIFU has a treatment time of about 12 minutes per milliliter, whereas the treatment time is about 30 minutes for RFA and about 15 minutes for MWA for a nodule volume of 4–5 ml. MWA was chosen for combined therapy as it yielded better results regarding the ablation zone, treatment time and had less side effects in comparison to other thermoablative techniques [12–14]. It is well established that RIT causes a volume reduction in an acceptable magnitude. Nevertheless, it is also well known that volume reduction is a slow process and improvement can only be observed 3 to 36 months after treatment whereas MWA immediately destroys the total nodule volume during therapy. Therefore, necrotic tissue and the onset of volume reduction can be observed instantly after treatment. Patients feel a relief of subjective symptoms, e.g. tension or swallowing problems. Another important aspect is the side effect-benefit ratio that has to be considered beyond a specific amount of calculated required radioiodine dose. Radioiodine-131 should only be administered up to a maximum level (in this institution: 1300 MBq) to avoid adverse events such as trachea stenosis and to reduce unreasonably dangerous irradiation to healthy tissue. According to Marinelli et al. [15], a reduced amount of radioiodine-131 leads to a reduced radiation dose and therefore to an insufficient treatment (or the necessity of a second RIT). The combination of MWA and RIT allows a more effective treatment in cases of large nodular goiters that could not have been sufficiently treated by a RIT monotherapy due to calculated required radioiodine doses beyond 1300 MBq. The pre-RIT reduction of thyroid volume by MWA leads to a reduction of required radioiodine dose and therefore enables a more sufficient and safer RIT. Based on the formula by Marinelli et al., the required activity can be decreased by reducing the target volume:

\[
\text{Activity [MBq]} = \frac{\text{Dose [Gy] \times Mass of target volume [g]}}{\text{constant \times max. uptake [%] \times eff. half-life [d]}}
\]

*Mass of target volume = vital thyroid volume – MWA ablated tissue (avital)

In an earlier study, the combined therapy showed promising results in volume reduction (24±6%), hospitalization time reduction (28±6%), which is important in Germany, and therefore a potential reduction of administered I-131-dose (24±6%) [16]. This study aims at assessing the efficacy of the combined MWA and I-131 treatment of benign thyroid diseases at a 3-month follow-up (3MFU), focusing on the development of thyroid function and thyroid volume.

**Materials and Methods**

**Patients**

15 patients (7 men and 8 women, median age: 55 years (27–79 years)) matching the entry criteria were recruited for the study. Every patient had one nodule. No previous surgeries or radioiodine therapies had taken place. 14 patients were treated for goiters, 1 because of Graves’ disease. 8 out of the 14 patients suffering from goiter, additionally, had autonomous tissue. The entry criteria were either: (a) growing goiters, (b) symptomatic benign thyroid nodules; hot, cold or indifferent (c) local compression symptoms, (d) cosmetic concerns, (e) high operative risk, (f) previous thyroidec- tomy or (g) refusal of surgery. The exclusion criteria were: (a) thyroids with retrosternal growth, (b) histological evidence for follicular proliferation or malignancy, (c) conspicuous Tc-99m-MIBI uptake in cold nodules, (c) abnormal calcitonin measurement as evidence for medullary thyroid cancer, (d) critical positions near vessels, trachea, esophagus or nerves.
The local ethics committee approved the study protocol and written informed consent was obtained from all subjects before starting therapy.

**Chronological overview**
1. Enrollment assessments
2. Radioiodine uptake test (RIUT) – one week before therapy
3. MWA, re-evaluation assessments, RIT – on the same day
4. 3-month follow-up (6-month follow-up)

**Assessments**
All patients underwent pre-therapy assessments, post-MWA assessments and assessments at 3MFU including US, laboratory tests and functional imaging with Tc-99m-Pertechnetate and in some cases Tc-99m-Methoxy-isobutyl-isonitril (MIBI).

**Ultrasound evaluation**
US imaging was conducted with a B-mode ultrasound scanner (Sonix Touch Ultrasound system, Ultrasound Medical Corporation, Richmond, Canada) to evaluate the volume, size, and composition of the nodules and thyroids.

**Laboratory evaluation**
All serum levels were determined with commercially available immunoassay kits.

A complete thyroid hormone status, including triiodothyronine (T3) determined by RIA (T3[I-125] RIA Kit, Isotop, Budapest, Hungary), thyroxine (T4) determined by RIA (T4[I-125] RIA Kit, Isotop, Budapest, Hungary), thyrotropin (TSH) determined by IRMA (SELCo® TSH rapid, Medipan GmbH, Dahlewitz, Germany) and thyroglobulin (Tg) determined by IRMA (Riason® Tg c.t., Labor GmbH, Graz-Seiersberg, Austria) was analyzed.

Moreover, antibody detection tests were performed, namely against thyroid peroxidase (TPOAb) determined by RIA (anti-TPO magnum, Medipan GmbH, Dahlewitz, Germany), thyroglobulin (TgAb) determined by RIA (anti-Tg magnum, Medipan GmbH, Dahlewitz, Germany) and thyrotropin receptor (TRAb) determined by RIA (TRAB Human RIA, Brahms GmbH, Henningsdorf, Germany).

Reference ranges were defined as follows:
T3: 1.0 – 3.3 nmol/L; T4: 55 – 170 nmol/L; TSH: 0.3 – 4.0 mE/L; Tg: 2 – 70 ng/mL; TPOAb: < 50 IU/ml; TgAb: < 50 IU/ml; TRAb: < 1.5 IU/L.

**Functional imaging**
All patients received Tc-99m-Pertechnetate and in some cases Tc-99m-MIBI-scans. Scintigraphic images were taken 20 minutes after administration of 75 MBq Tc-99m-Pertechnetate and recorded with a scintillation camera (Mediso Nucline® TH/22). Patients with “cold” nodules were re-evaluated with a Tc-99m-MIBI scan to exclude malignancy. Scintigraphic images were taken 10 and 60 minutes after administration of 500 MBq Tc-99m-MIBI.

**Radioiodine therapy**
Four to five hours after the treatment and re-evaluation of nodule and thyroid volume, Tc-99m-Pertechnetate uptake and laboratory values, the physician administered the I-131 capsule with the specific individually calculated I-131 dose. Patients treated with methimazole (M MI) were asked to discontinue taking the medication to obtain suppressed levels of TSH at the time of I-131 administration. I-131 therapeutic activity was aimed at delivering 150 Gy to patients with a goiter and 250 Gy to the patient with Graves’ disease.
Results

Volume reduction
In every patient the nodule was completely destroyed by MWA. A comparison of thyroid volumes before therapy and at 3MFU (Fig. 2) shows a significant mean volume reduction of 26.4 ml ± 7.9 ml, implying a mean relative reduction of 30.5 % ± 4.6 % (p < 0.05) (range of volume reduction: 18 – 47 %). Table 1 presents a detailed list of volume reduction achieved in every patient. Fig. 3 depicts the volume reduction achieved in patient no. 10.

Activity and hospitalization time (HT) reduction
Dosimetric results are summarized in Table 2. The mean required activity without reducing target volume by MWA was 2116 ± 701 MBq, while the mean required activity utilizing MWA prior to RIT was 1553 ± 537 MBq. This implies a mean absolute activity reduction of 563 ± 102 MBq and a relative reduction of 26.6 % ± 4.8 % (p < 0.05) using the combined therapy. Additionally, there was a significant reduction of hospitalization time for some patients. The mean hospitalization time for classic RIT was 6.5 ± 1.8 days to reach the permissible value of 250 MBq to be discharged from hospital, whereas the hospitalization time for combined therapy was 4.5 ± 1.4 days. This reflects a mean time reduction of 2 ± 0.7 days and a relative reduction of 30.9 % ± 19.9 % (p < 0.05).

Blood tests
All serum levels before MWA and at 3MFU are summarized in Table 3. T3 and T4 levels remained within normal limits in all patients. TSH levels improved or remained in normal limits in 13 out of 15 patients. Before treatment and at 3MFU, two patients (no.6 and no.15) showed values below the euthyroid range. However, the patients had no signs of hyperthyroidism. In all patients Tg levels were elevated significantly in the measurements after MWA but decreased back to baseline values at 3MFU.

Antibody measurement
Antibody measurements are summarized in Table 4. The patient treated for Grave’s disease (no.4) showed increased anti-

Fig. 1 A Ultrasound examination to locate and recalculate a thyroid nodule. B Subcutaneous and intracapsular (thyroid) infiltration anesthesia with Scandicain (0.9 %; 10 ml) to prevent pain and create a fluid protection area, protecting vital structures of the neck (trachea, esophagus, carotid artery and nerve). C Positioning of the internally cooled microwave antenna. D, E During treatment hyperchogenic areas and microbubbles surrounding the antenna tip can be observed. F Ultrasound guidance allows accurate replacement of the antenna by moving the tip of the antenna backwards and relocating it in a non-ablated area of the nodule.

Abb. 1 A Ultraschalluntersuchung zur Lokalisation- und Größenbestimmung des Knotens. B Um Schmerzen vorzubeugen und einen flüssigen Schutzwall für die Halsorgane (A. carotis, Nerven, Trachea und Ösophagus) zu schaffen, wird subkutan und auch in die Schilddrüsenkapsel Scandicain (0,9 %; 10 ml) gespritzt. C Positionierung der gekühlten Mikrowellenantenne. D, E Während der Behandlung kann man an der Spitze der Antenne hyperchogene Regionen und "microbubbles" erkennen. F Unter Ultraschallsicht ist es möglich die Antennenspitze zurück zu ziehen und akkurat in einen nicht-abladierten Teil des Knotens vorzuschieben.

Fig. 2 Comparison of thyroid volumes before combined therapy and at 3-month follow-up (* p < 0.05).

Abb. 2 Vergleich der Schilddrüsenvolumen vor der Kombinationstherapie und bei der 3-monatigen Kontrolluntersuchung (* p < 0,05).
Tg, TRAb and anti-TPO levels before treatment and at 3MFU. The TSH level in this patient increased to normal levels 3 months after treatment. Another patient had elevated anti-TPO before treatment and at follow-up, showing no symptoms of Hashimoto’s thyroiditis or Graves’ disease before or after therapy. The TRAb value was elevated at 3MFU for one patient (no. 7). Due to the combination of MWA and RIT, it cannot be clearly determined whether TRAb development is a result of MWA or RIT. Correspondingly, only one patient was found to develop TRAb during 3MFU, nevertheless, staying euthyroid.

Complications
No serious complications occurred during treatment. There were no interruptions and discomfort stayed at a minimum. The following complications were reported for MWA: mild pain during the procedure (2/15), mild superficial hematomas due to pressure of the US probe (1/15) and first-degree burns alongside the puncture channel which disappeared within a couple of days (1/15). Ultrasound assessments assured that the hematomas did not reach deeper tissue layers. Serious complaints, such as swallowing problems, vagal reactions or subjectively noticeable voice changes, did not occur.

Discussion
Surgery and RIT are often recommended as the first option for the therapy of nodular goiters. As both of the therapies involve drawbacks and complications, e.g. scar formation, nerve lesions, hypothyroidism or thyroiditis [1, 18], and surgery is often contraindicated or refused by older patients due to high surgical risk because of cardiopulmonary diseases, attention is increasingly focused on non-surgical alternative treatments.

In the last two decades several nonsurgical, image-guided, minimally invasive approaches including RFA [7, 19], LAT [8, 20], PEIT [21], HIFU [8, 22] and MWA [1, 10, 11, 23] have been developed for the efficient treatment of thyroid nodules, without the risk of general anesthesia and while preserving normal thyroid function. Nevertheless, there is barely any research and results on thermal ablation of very large goiters as the treatment is quite time-consuming, needs more treatment sessions and is accompanied by increased discomfort [24]. In an evaluation of the efficiency of LA for thyroid nodules, Spiezia et al. [25] recommends adding radioiodine therapy for the effective treatment of very large nodular goiters. However, large goiters are frequently seen as a relative contraindication for the utilization of RIT as the risk...
of local symptoms, hypothyroidism and autoimmune thyroiditis is increased and the volume reduction is slow [26, 27]. For these patients higher activities of I-131 are required. As shown in Table 1, preceding thermal ablative treatment not only accelerates the reduction of total thyroid volume but also reduces the target volume and, consequently, activity for I-131 therapy.

Until now, there have been two studies analyzing the impact of combined therapies on nodular goiters. One reports efficient treatment using ultrasound-guided PEIT combined with RIT in patients with toxic thyroid nodules [28]. PEIT, however, presents limitations in solid nodules and is currently recommended for cystic lesions only [29]. Chianelli et al. [5] combined LAT and RIT.

### Table 2

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Goiter + MFA</td>
<td>150</td>
<td>196</td>
<td>595</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Goiter</td>
<td>150</td>
<td>204</td>
<td>3043</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>Goiter</td>
<td>150</td>
<td>202</td>
<td>377</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>Graves' disease</td>
<td>250</td>
<td>250</td>
<td>553</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>Goiter + DPD</td>
<td>150</td>
<td>258</td>
<td>2865</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>Goiter + DPD</td>
<td>150</td>
<td>257</td>
<td>279</td>
<td>14</td>
<td>11</td>
</tr>
<tr>
<td>7</td>
<td>Goiter</td>
<td>150</td>
<td>250</td>
<td>1410</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>8</td>
<td>Goiter</td>
<td>150</td>
<td>249</td>
<td>1669</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>Goiter</td>
<td>150</td>
<td>247</td>
<td>1151</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>Goiter</td>
<td>150</td>
<td>246</td>
<td>2270</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>11</td>
<td>Goiter + MFA</td>
<td>150</td>
<td>245</td>
<td>5650</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>12</td>
<td>Goiter + MFA</td>
<td>150</td>
<td>244</td>
<td>1294</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>13</td>
<td>Goiter + DPD</td>
<td>150</td>
<td>243</td>
<td>1758</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>14</td>
<td>Goiter + MFA</td>
<td>150</td>
<td>242</td>
<td>3000</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>Goiter + DPD</td>
<td>150</td>
<td>241</td>
<td>3520</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Average</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.5 ± 1.8</td>
<td>4.5 ± 1.4</td>
</tr>
</tbody>
</table>

1 p < 0.05

### Table 3

Laboratory tests before combined therapy and at 3-month follow-up (3MFU). Additionally, hTg levels after MWA are noted as these increased strongly.

<table>
<thead>
<tr>
<th>Patient</th>
<th>T3 [nmol/l] (1.0 – 3.3)</th>
<th>T4 [nmol/l] (95 – 170)</th>
<th>TSH-basal [mE/l] (0.3 – 4.0)</th>
<th>hTg [ng/ml] (Athyreote &lt; 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>before therapy 3MFU</td>
<td>before therapy 3MFU</td>
<td>before therapy 3MFU</td>
<td>before therapy 3MFU after MWA 3MFU</td>
</tr>
<tr>
<td>1</td>
<td>1.5</td>
<td>1.8</td>
<td>78</td>
<td>84</td>
</tr>
<tr>
<td>2</td>
<td>1.9</td>
<td>2.2</td>
<td>64</td>
<td>75</td>
</tr>
<tr>
<td>3</td>
<td>2.1</td>
<td>2.0</td>
<td>91</td>
<td>89</td>
</tr>
<tr>
<td>4</td>
<td>1.2</td>
<td>1.3</td>
<td>75</td>
<td>89</td>
</tr>
<tr>
<td>5</td>
<td>1.9</td>
<td>2.1</td>
<td>87</td>
<td>101</td>
</tr>
<tr>
<td>6</td>
<td>1.6</td>
<td>1.9</td>
<td>79</td>
<td>68</td>
</tr>
<tr>
<td>7</td>
<td>1.8</td>
<td>1.4</td>
<td>89</td>
<td>122</td>
</tr>
<tr>
<td>8</td>
<td>1.7</td>
<td>1.6</td>
<td>55</td>
<td>72</td>
</tr>
<tr>
<td>9</td>
<td>1.9</td>
<td>1.8</td>
<td>99</td>
<td>89</td>
</tr>
<tr>
<td>10</td>
<td>1.5</td>
<td>1.6</td>
<td>73</td>
<td>86</td>
</tr>
<tr>
<td>11</td>
<td>5.0</td>
<td>1.4</td>
<td>56</td>
<td>62</td>
</tr>
<tr>
<td>12</td>
<td>1.5</td>
<td>1.3</td>
<td>85</td>
<td>71</td>
</tr>
<tr>
<td>13</td>
<td>2.7</td>
<td>2.3</td>
<td>84</td>
<td>87</td>
</tr>
<tr>
<td>14</td>
<td>1.7</td>
<td>1.7</td>
<td>60</td>
<td>86</td>
</tr>
<tr>
<td>15</td>
<td>1.4</td>
<td>1.7</td>
<td>70</td>
<td>86</td>
</tr>
<tr>
<td>MV/A</td>
<td>1.7 / 2.0</td>
<td>1.7 / 1.7</td>
<td>79 / 79</td>
<td>86 / 84</td>
</tr>
</tbody>
</table>

MV: median value, A: average, x: not evaluated, T3 = triiodthyronine, T4 = thyroxine, TSH = thyrotropin, hTg = thyroglobulin; reference ranges in brackets. T3 = Triiodthyronin, T4 = Thyroxin, TSH = Thyreotropin, hTg = Thyreoglobulin; Referenzbereiche in Klammern.

Korkusuz H et al. Combination of Ultrasound-Guided... Fortschr Röntgenstr 2016; 188: 60–68
for the treatment of toxic nodular goiters and obtained a reduction of 71.3 ± 13.4% in nodule volume and a reduction of 21.1 ± 8.1% in administered radioiodine activity. Nevertheless, LAT presents limitations in autonomously functioning thyroid nodules. Chianelli claims that the favorable results are inconsistent, and the normalization of thyroid function usually requires repeated treatment sessions [30]. MWA is applicable on any kind of nodule, i.e., hot, cold, indifferent, cystic, solid or mixed, and has various advantages compared to the above-mentioned techniques. A previous study [16] introduced the positive results of combined MWA and radioiodine therapy. The statistically significant thyroid volume reduction of 24 ± 6% (p < 0.05), the reduction in administered I-131 activity by 24 ± 6% (p < 0.05), the good treatment response and the small number of adverse events demonstrated that the combined MWA and RIT therapy could be an effective and safe conservative approach to treating large nodular goiters. An additional study approved the therapy for the treatment of patients with simultaneously hypo- and hyperfunctioning thyroid nodules [31].

The presented study focused on thyroid volume and thyroid function at 3MFU. Regarding surgery, especially thyroidectomy, hypothyroidism cannot be prevented and lifelong substitution of thyroid hormones is necessary. Concerning the impact of minimally invasive techniques on thyroid functions, there have only been a few reports. Transient hyperthyroidism is described after RFA [32]. Hypothyroidism is reported more often, especially, subsequent to PEIT for the treatment of autonomously functioning nodules [33]. After LAT and RFA, hypothyroidism occurs rarely [34]. In a few cases hypothyroidism is also reported after radioiodine therapy. This contributes to the inevitable impact of I-131 on the entire thyroid gland [35].

A recent 3-month follow-up study proved that MWA does not affect thyroid function in patients with benign thyroid nodules [36]. As hypothyroidism often develops after a period of three months post-therapy, data has to be treated with caution and it cannot be completely excluded that hypothyroidism will occur. However, the 4 out of 15 patients in this study that went through a 6-month follow-up (6MFU) did not develop hypothyroidism. Laboratory parameters TSH, T3 and T4 did not change significantly after MWA or at 3MFU/6MFU of the combined therapy (p > 0.05) (Table 3). Patient no. 4 and no. 8 even improved to normal TSH levels at 3MFU. This demonstrates the positive effect of combined therapy on thyroid function. For one patient (no. 6) the TSH values before and 3 months after treatment were lower than normal levels without showing any signs of hyperthyroidism. Consequently there is no correlation between therapy and the low levels. In this case therapy had no effect on thyroid function, positive or negative.

However, for all patients the thyroglobulin (Tg) levels were elevated significantly in the measurements after MWA but decreased back to baseline at 3MFU. Tg is used for measurements of thyroid tissue injury, such as growth factor and tumor marker. One explanation might be that Tg values increased after ablation due to injured necrotic thyroid tissue and recovered during the 3MFU period due to healing processes. Similar findings were reported by Valcavi et al. [37] after LA of benign thyroid nodules. It cannot be clearly determined whether the elevated TRAb development in patient no. 7 (Table 4) at 3MFU is a result of MWA or RIT. The further planned procedure would have been to treat the developed Graves’ disease with RIT. Fortunately, this was not necessary as pre-RIT assessments showed that the TRAb level decreased back to the normal range. Nevertheless, Monzani et al. [33] concluded that a massive release of partially denatured TSH receptors could be a reason for the development of increasing TRAb levels after ablation of toxic nodules with PEIT. Therefore, an immunization process caused by MWA cannot be excluded completely. Nygaard et al. [38] demonstrated that immunization processes can be triggered by I-131 therapy, not...

Table 4 Antibody levels before combined therapy, after microwave ablation (MWA) and at 3-month follow-up (3MFU).

<table>
<thead>
<tr>
<th>patient</th>
<th>TRAb (pos. &gt; 1.5)</th>
<th>TgAb (pos. &gt; 50)</th>
<th>TPOAb (pos. &gt; 50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>before therapy</td>
<td>after MWA</td>
<td>3MFU</td>
<td>before therapy</td>
</tr>
<tr>
<td>1</td>
<td>0.09</td>
<td>0.07</td>
<td>0.78</td>
</tr>
<tr>
<td>2</td>
<td>0.10</td>
<td>0.20</td>
<td>0.31</td>
</tr>
<tr>
<td>3</td>
<td>0.00</td>
<td>0.20</td>
<td>0.34</td>
</tr>
<tr>
<td>4</td>
<td>4.40</td>
<td>3.60</td>
<td>17.90</td>
</tr>
<tr>
<td>5</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>6</td>
<td>0.10</td>
<td>0.83</td>
<td>0.20</td>
</tr>
<tr>
<td>7</td>
<td>0.20</td>
<td>0.60</td>
<td>4.20</td>
</tr>
<tr>
<td>8</td>
<td>0.50</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>9</td>
<td>0.50</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>10</td>
<td>0.30</td>
<td>0.18</td>
<td>0.00</td>
</tr>
<tr>
<td>11</td>
<td>0.27</td>
<td>0.00</td>
<td>0.50</td>
</tr>
<tr>
<td>12</td>
<td>0.00</td>
<td>0.35</td>
<td>0.00</td>
</tr>
<tr>
<td>13</td>
<td>0.29</td>
<td>0.60</td>
<td>0.00</td>
</tr>
<tr>
<td>14</td>
<td>0.05</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>15</td>
<td>0.50</td>
<td>0.30</td>
<td>0.05</td>
</tr>
</tbody>
</table>

MV/A 0.2/0.5 0.2/0.5 0/1.6 4/17 6/14 10/34 10/147 10/132 9/528

MV: median value, A: average, x: not evaluated, TgAb = thyroglobulin antibodies, TRAb = thyrotropin receptors antibodies, TPOAb = thyroid peroxidase antibodies; reference ranges in brackets.
only related to radiation thyroiditis but also as a Graves’-like hyperthyroidism induced by TRAb. Finally, it can reasonably be assumed that the elevated TRAb level was an effect of RIT as there is more evidence for antibody developments after RIT [38, 39] and hardly any for MWA. This case has to be intensively investigated and observed in future studies.

Furthermore, it is important for future therapy to investigate if and to what extent combined therapy is more effective than traditional RIT. The only study comparing a combined therapy of thermal ablation and RIT versus traditional RIT monotherapy in a head to head study was carried out by Chianelli et al. [5], and found faster volume reduction and symptom relief and faster control of hyperthyroidism utilizing the combined therapy. In order to underline and verify the efficacy of the combined therapy, additional studies with more patients and extended follow-up periods are required. Thyroid function and volume development must be observed continuously.

**Conclusion**

The 3-month follow-up study shows that the combined therapy of MWA and RIT displays an effective approach for the treatment of large benign nodular goiters. Very large goiters that had to be operated according to the German nuclear medicine guidelines could be treated conservatively and safely. A major benefit compared to surgery is the improvement or preservation of thyroid function accompanied by statistically significant thyroid volume reduction. Thyroid hormone substitution would not be required. Nevertheless, due to the limited number of patients, future studies with a stronger data base will have to investigate the long-term benefits.

**Clinical relevance of the study**

- The combination of MWA with RIT significantly reduces goiter volume, administered activity and hospitalization time.
- Thyroid function is preserved at the 3-month follow-up.
- Combined therapy can be seen as an innovative and conservative approach to treating very large benign nodular goiters.

**References**

7. Spiezia S, Garberoglio R, Milone F et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid 2009; 19: 219 – 225
38 Nygaard B, Faber J, Veje A et al. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid 1999; 9: 477 – 481